Postexposure prevention of progressive vaccinia in SCID mice treated with vaccinia immune globulin

Clinical and Vaccine Immunology

Volumn 18, Issue 1, 2011, Pages 67-74

  Fisher, R W ^a   Reed, J L ^a   Snoy, P J ^a   Mikolajczyk, M G ^a   Bray, M ^b   Scott, D E ^a   Kennedy, M C ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; VACCINIA ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; IMMUNOCOMPROMISED PATIENT; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGRESSIVE VACCINIA; SURVIVAL RATE; SURVIVAL TIME; VACCINATION REACTION;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; CYTOSINE; DRUG THERAPY, COMBINATION; HELA CELLS; HUMANS; IMMUNOGLOBULINS; MICE; MICE, SCID; PHOSPHONIC ACIDS; POST-EXPOSURE PROPHYLAXIS; SKIN; SURVIVAL RATE; VACCINATION; VACCINIA; VACCINIA VIRUS; VERO CELLS;

EID: 78650895508     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00280-10     Document Type: Article

References (42)

1. Ahmad, N., P. Cheng, and H. Mukhtar. 2000. Cell cycle dysregulation by green tea polyphenol epigallocatechin-3-gallate. Biochem. Biophys. Res. Commun. 275:328-334.
2. Barbero, G. J., A. Gray, T. F. Scott, and C. H. Kempe. 1955. Vaccinia gangrenosa treated with hyperimmune vaccinal gamma globulin. Pediatrics 16:609-618.
3. Belyakov, I. M., et al. 2003. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc. Natl. Acad. Sci. U. S. A. 100:9458-9463.
4. Benhnia, M. R., et al. 2009. Vaccinia virus extracellular enveloped virion neutralization in vitro and protection in vivo depend on complement. J. Virol. 83:1201-1215.
5. Bray, M., and M. E. Wright. 2003. Progressive vaccinia. Clin. Infect. Dis. 36:766-774.
6. Bugbee, L. M., A. A. Like, and R. B. Stewart. 1960. The effects of cortisone on intradermally induced vaccinia infection in rabbits. J. Infect. Dis. 106: 166-173.
7. Centers for Disease Control and Prevention. 2009. Progressive vaccinia in a military smallpox vaccinee - United States, 2009. MMWR Morb. Mortal. Wkly. Rep. 58:532-536.
8. Daëron, M., O. Malbec, S. Latour, M. Arock, and W. H. Fridman. 1995. Regulation of high-affinity IgE receptor-mediated mast cell activation by murine low-affinity IgG receptors. J. Clin. Invest. 95:577-585.
9. Ding, H., et al. 2009. Partial protection against Helicobacter pylori in the absence of mast cells in mice. Infect. Immun. 77:5543-5550.
10. Dvorak, H. F., and M. S. Hirsch. 1971. Role of basophilic leukocytes in cellular immunity to vaccinia virus infection. J. Immunol. 107:1576-1582.
11. Edghill-Smith, Y., et al. 2005. Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat. Med. 11:740-747.
12. Fenner, F. 1948. The clinical features and pathogenesis of mouse-pox (infectious ectromelia of mice). J. Pathol. Bacteriol. 60:529-552.
13. Fenner, F., D. A. Henderson, I. Arita, Z. Ježek, and I. D. Ladnyi. 1988. Smallpox and its eradication. World Health Organization, Geneva, Switzerland.
14. Foong, Y. Y., D. A. Jans, M. S. Rolph, M. E. Gahan, and S. Mahalingam. 2009. Interleukin-15 mediates potent antiviral responses via an interferondependent mechanism. Virology 393:228-237.
15. Fulginiti, V. A., A. Papier, J. M. Lane, J. M. Neff, and D. A. Henderson. 2003. Smallpox vaccination: a review, part II. Adverse events. Clin. Infect. Dis. 37:251-271.
16. Fulginiti, V. A., C. H. Kempe, W. E. Hathaway, D. S. Pearlman, O. F. Sieber, J. J. Eller, J. J. Joyner, and A. Robinson. 1967. Progression vaccinia in immunologically deficient individuals. Birth Defects 4:129-145.
17. Gerber, A., et al. 2004. Proteasome inhibitors modulate chemokine production in lung epithelial and monocytic cells. Eur. Respir. J. 24:40-48.
18. Good, R. A., S. J. Zak, R. M. Condie, and R. A. Bridges. 1960. Clinical investigation of patients with agammaglobulinemia and hypogammaglobulinemia. Pediatr. Clin. North Am. 7:397-433.
19. Hanlon, C. A., et al. 1997. A recombinant vaccinia-rabies virus in the immunocompromised host: oral innocuity, progressive parenteral infection, and therapeutics. Vaccine 15:140-148.
20. Kawakami, Y., et al. 2009. Inhibition of NK cell activity by IL-17 allows vaccinia virus to induce severe skin lesions in a mouse model of eczema vaccinatum. J. Exp. Med. 206:1219-1225.
21. Keidan, S. E., K. McCarthy, and J. C. Haworth. 1953. Fatal generalized vaccinia with failure of antibody production and absence of serum gamma globulin. Arch. Dis. Child. 28:110-116.
22. Law, M., M. M. Putz, and G. L. Smith. 2005. An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model. J. Gen. Virol. 86:991-1000.
23. Lustig, S., et al. 2009. Effective post-exposure protection against lethal orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response. Vaccine 27:1691-1699.
24. Neyts, J., and E. De Clercq. 1993. Efficacy of (S)-1-(3-hydroxy-2- phosphonylmethoxypropyl) cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice. J. Med. Virol. 41:242-246.
25. Neyts, J., P. Leyssen, E. Verbeken, and E. De Clercq. 2004. Efficacy of cidofovir in a murine model of disseminated progressive vaccinia. Antimicrob. Agents Chemother. 48:2267-2273.
26. Neyts, J., E. Verbeken, and E. De Clercq. 2002. Effect of 5-iodo-2′-deoxyuridine on vaccinia virus (orthopoxvirus) infections in mice. Antimicrob. Agents Chemother. 46:2842-2847.
27. Okayama, Y., A. S. Kirshenbaum, and D. D. Metcalfe. 2000. Expression of a functional high-affinity IgG receptor, Fc gamma RI, on human mast cells: up-regulation by IFN-gamma. J. Immunol. 164:4332-4339.
28. Osorio, J. E., K. P. Iams, C. U. Meteyer, and T. E. Rocke. 2009. Comparison of monkeypox viruses pathogenesis in mice by in vivo imaging. PLoS One 4:e6592.
29. Postigo, A., M. C. Martin, M. P. Dodding, and M. Way. 2009. Vaccinia-induced epidermal growth factor receptor-MEK signalling and the antiapoptotic protein F1L synergize to suppress cell death during infection. Cell. Microbiol. 11:1208-1218.
30. Quenelle, D. C., D. J. Collins, and E. R. Kern. 2004. Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir. Antiviral Res. 63:33-40.
31. Quenelle, D. C., et al. 2004. Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob. Agents Chemother. 48:404-412.
32. Redfield, R. R., et al. 1987. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease. N. Engl. J. Med. 316:673-676.
33. Satheshkumar, P. S., L. C. Anton, P. Sanz, and B. Moss. 2009. Inhibition of the ubiquitin-proteasome system prevents vaccinia virus DNA replication and expression of intermediate and late genes. J. Virol. 83:2469-2479.
34. Shearer, J. D., L. Siemann, M. Gerkovich, and R. V. House. 2005. Biological activity of an intravenous preparation of human vaccinia immune globulin in mouse models of vaccinia virus infection. Antimicrob. Agents Chemother. 49:2634-2641.
35. Shelburne, C. P., et al. 2009. Mast cells augment adaptive immunity by orchestrating dendritic cell trafficking through infected tissues. Cell Host Microbe 6:331-342.
36. Smee, D. F., K. W. Bailey, M. H. Wong, and R. W. Sidwell. 2001. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice. Antiviral Res. 52:55-62.
37. Smee, D. F., K. W. Bailey, M. H. Wong, M. K. Wandersee, and R. W. Sidwell. 2004. Topical cidofovir is more effective than is parenteral therapy for treatment of progressive vaccinia in immunocompromised mice. J. Infect. Dis. 190:1132-1139.
38. Vora, S., et al. 2008. Severe eczema vaccinatum in a household contact of a smallpox vaccinee. Clin. Infect. Dis. 46:1555-1561.
39. Wharton, M., et al. 2003. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm. Rep. 52:1-16.
40. Worthington, M., A. S. Rabson, and S. Baron. 1972. Mechanism of recovery from systemic vaccinia virus infection. I. The effects of cyclophosphamide. J. Exp. Med. 136:277-290.
41. Xiao, Y., et al. 2007. A protein-based smallpox vaccine protects mice from vaccinia and ectromelia virus challenges when given as a prime and single boost. Vaccine 25:1214-1224.
42. Zuckier, L. S., L. Georgescu, C. J. Chang, M. D. Scharff, and S. L. Morrison. 1994. The use of severe combined immunodeficiency mice to study the metabolism of human immunoglobulin G. Cancer 73:794-799.